What were the key takeaways from Vicarious Surgical’s earnings call?

What does Vicarious Surgical do and what are its main business segments?

What is Vicarious Surgical's gross profit margin?

What factors drove the changes in Vicarious Surgical's revenue and profit?

What were the key takeaways from Vicarious Surgical's earnings call?

Did Vicarious Surgical beat or miss consensus estimates last quarter?

What guidance did Vicarious Surgical's management provide for the next earnings period?

What is the market's earnings forecast for Vicarious Surgical next quarter?

- **2026 Design Freeze On Track**: Despite 15% workforce reduction, maintaining clinical trial timelines via targeted outsourcing.
- **$10M+ Annualized Cost Savings**: 35% YoY expense reduction, with 2026 burn target <$40M.
- **Surgeon-Tested Efficiency**: 65% reduction in complex surgical procedures, validating commercial viability.
- **Transparency Boost**: Weekly LinkedIn updates to replace quarterly earnings calls for real-time progress.

**【CEO Summary Section】**
- **Design Freeze Milestone**: Targeting completion of production-equivalent system by end-2026, with focus on maintaining clinical trial and commercialization timelines despite restructuring efforts.
- **Cost Reduction Strategy**: 15% headcount reduction across non-core functions, engaging PA Consulting for outsourcing RFPs to reduce 2026 cash burn by ~$10M+.
- **Transparency Initiative**: Launching weekly LinkedIn updates on control builds (e.g., PDV2 progress), quality management system implementation, and surgeon testing results (e.g., 65% reduction in IPOM hernia suturing time from 40min to 14min).

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: 
  - Total operating expenses: $11.5M (35% YoY decline)
  - GAAP net loss: $11.1M ($1.86/share) vs. $17.1M ($2.90/share) prior year
  - Cash burn rate: $10.5M/Q3, with $5.9M raised in Oct registered direct offering
- **Expense Optimization**: R&D down 28% YoY, G&A down 45%, sales & marketing down 71%.

**【Q&A Key Highlights】**
- **Outsourcing Impact**: Consulting engagement to complete by end-Nov, with RFPs for capital equipment outsourcing to begin Q1 2026.
- **Surgeon Testing Success**: 10+ surgeons tested system stability, with dramatic improvement in suturing efficiency (40min → 14min).
- **Hospital Partnerships**: Strong engagement with health systems, with surgeons requesting hands-on demos post-commercialization.

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

- **Strategic Shift**: Delayed FCU trial to prioritize production-ready system development, expected to enhance long-term commercial success.
- **Financial Discipline**: 24% YoY expense reduction to $13.5M, with $24M cash on hand and $50M annual cash burn guidance.
- **Leadership Transition**: New CEO Stephen From focuses on technical excellence and resource optimization.
- **Assessment Period**: 4-6 week evaluation to determine system readiness and revised clinical timelines.

**【Management Opening Remarks】**
- Adam Sachs introduced Stephen From as the new CEO, emphasizing his experience in healthcare and med tech. Sachs transitioned to President, focusing on product development and clinical programs.
- The company is undergoing a strategic shift to prioritize completing a production-equivalent robotic surgery system over near-term clinical trials.

**【CEO Commentary】**
- Stephen From highlighted the need to finalize a production-ready system for full verification, delaying the first clinical use (FCU) trial beyond 2025.
- A 4-6 week assessment will evaluate system readiness, with resources redirected from non-production testing to ensure commercial viability.
- The shift aims to avoid resource diversion and focus on long-term value through a robust, scalable system.

**【CFO Financial Commentary】**
- Q2 2025 operating expenses decreased 24% YoY to $13.5M, driven by reduced R&D (-16%), G&A (-28%), and sales (-75%).
- GAAP net loss was $13.2M, with cash reserves of $24M and full-year cash burn guidance of $50M.
- The company maintains disciplined spending to support strategic priorities.

**【Q&A Highlights】**
- **Clinical Trial Delay**: Postponing FCU to focus on production readiness; no material cash impact from trial preparation.
- **Resource Allocation**: Shift to system verification aims to reduce future costs and improve commercial success odds.
- **Milestones**: Assessment period will clarify timelines for system completion and subsequent clinical milestones.
- **Cash Position**: Current runway supports 2025 goals, with no immediate capital raise plans.


Vicarious Surgical (RBOT)-12 Aug 25-2025 Q2 Earnings call transcript

- **2025 Clinical Catalysts**: First human cases on track for late 2025, supported by completed instrument testing and mid-2025 regulatory filing.
- **Financial Discipline**: Q1 cash burn $12M vs. $50M annual target; exploring financing amid $37M cash balance and supportive investor base.
- **Strategic Leverage**: UMass partnership driving workflow optimization, with early collaboration accelerating pre-commercial adoption.

**【CEO Business Update】**
- **Clinical Milestone Progress**: First human cases expected in late 2025, with technical dossier submission mid-2025. Instrument sets for biocompatibility and sterility testing completed.
- **Strategic Partnerships**: Announced collaboration with UMass Memorial Medical Center to optimize perioperative workflows and surgeon education. Existing partnerships include HCA Healthcare, University Hospitals, and Intermountain Health.
- **Supply Chain Stability**: Overcame Q1 supply chain challenges, with no delays impacting Q1 milestones. Team confident in managing complex system components.

**【CFO Financial Review】**
- **Q1 2025 Financials**: Operating expenses $15.7M (2% YoY decrease). R&D: $9.4M, G&A: $5.3M, Sales & Marketing: $1M (flat YoY). Adjusted net loss $15.3M ($2.58/share), same as Q1 2024.
- **Cash Position**: $37M cash balance, Q1 cash burn $12M. Full-year 2025 cash burn expected at $50M. Evaluating financing options amid supportive investor base.

**【Q&A Key Takeaways】**
- **Funding Assurance**: Management prioritizing disciplined spending and exploring financing around upcoming milestones. Insider base remains supportive.
- **Regulatory Timeline**: Technical dossier submission mid-2025, with assumptions based on historical agency review times for similar devices. Anticipate potential back-and-forth but remain on track for 2025 first-in-human trials.
- **Partnership Impact**: UMass collaboration already informing workflow design, with focus on streamlined OR processes and surgeon training. Commercial benefits expected post-approval, but early collaboration accelerates adoption readiness.

Vicarious Surgical (RBOT)-12 May 25-2025 Q1 Earnings call transcript

- **V1.0 System Validation**: Successful Cadaver Lab testing confirms preclinical functionality, setting stage for late 2025 human trials.
- **Supply Chain Recovery**: Resolved component delays, but clinical trial start pushed to year-end 2025.
- **Financial Discipline**: 17% YoY operating expense reduction, $49M cash burn aligned with guidance.
- **Partnership Expansion**: New academic health network collaborations enhance clinical training and post-market validation capabilities.
- **Regulatory Momentum**: Ministry of Health dossier submission expected mid-2025, with FDA pre-submission collaboration ongoing.


**【Management Opening Remarks】**
- Kaitlyn Brosco introduced the call, highlighting the release of 2024 Q4 and full-year financial results.
- Reminder of forward-looking statements and associated risks, including regulatory approvals and financial performance uncertainties.

**【CEO Summary Section】**
- **V1.0 System Integration Success**: Completed Cadaver Lab testing, validating the V1.0 system's functionality and performance in preclinical settings.
- **Innovative Design Features**: Decoupled actuators enable single 18mm incision, 13 degrees of freedom per instrument, and advanced AI capabilities for future enhancements.
- **Hospital Partnerships**: Expanded partnerships with LSU Health New Orleans, Temple Health, and UI Health for clinical training and post-market evaluation.
- **Clinical Trial Timeline**: First human cases expected in late 2025, with pivotal trial启动后. Regulatory dossier submission to Ministry of Health anticipated mid-2025.
- **Supply Chain Challenges**: Delays with key suppliers impacted manufacturing, but resolved gated components; clinical trial inventory build progressing.

**【CFO Financial Commentary】**
- **Full-Year 2024 Financials**: Total operating expenses $66.6M (-17% YoY), R&D $40.2M (-15% YoY), G&A $21.9M (-19% YoY), Sales & Marketing $4.5M (-27% YoY).
- **Net Loss**: Adjusted net loss $63.3M ($10.75/share) vs. $76.3M ($15.67/share) in 2023.
- **Cash Management**: Cash burn $49M (aligned with guidance), ending 2024 with $49M in cash equivalents.
- **2025 Outlook**: Anticipated cash burn of ~$50M, with focus on strategic balance sheet reinforcement.

**【Q&A Key Highlights】**
- **Supply Chain Transparency**: Delays caused by sub-tier supplier financial issues resolved; no current gated components.
- **Clinical Trial Timing**: First human cases in late 2025; pivotal trial design to be finalized post-initial cases.
- **Regulatory Feedback**: Positive engagement with FDA under Safer Technologies program; sites express confidence in system and interest in post-approval adoption.
- **Manufacturing Progress**: Capital systems nearing completion; instruments in production, with cost improvements identified during testing.


RBOT

RBOT fundamentals

Earnings Call

You can ask Aime